What are the recommended management strategies for asymptomatic pulmonary embolism, symptomatic (normotensive) pulmonary embolism, submassive (intermediate‑risk) pulmonary embolism, and massive (high‑risk) pulmonary embolism?

Treatment of Pulmonary Embolism by Risk Category

Asymptomatic Pulmonary Embolism

Treat asymptomatic PE identically to symptomatic low-risk PE with therapeutic anticoagulation for at least 3 months. 1

• Initiate anticoagulation immediately upon diagnosis, even in the absence of symptoms 1
• Prefer a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, dabigatran, or edoxaban over vitamin K antagonists (VKAs) 1
• If using LMWH or fondaparinux as initial therapy, these are preferred over unfractionated heparin in hemodynamically stable patients 1
• Dabigatran and edoxaban require initial parenteral anticoagulation (5-10 days) before transitioning to oral therapy, while rivaroxaban and apixaban can be started immediately 1, 2

---

Symptomatic PE (Low-Risk, Hemodynamically Stable)

Start a DOAC immediately as first-line therapy without requiring initial parenteral anticoagulation (for rivaroxaban or apixaban). 1

Initial Anticoagulation Options:

• DOACs are recommended over VKAs with Class I, Level A evidence 1
• If parenteral anticoagulation is chosen initially, LMWH or fondaparinux is preferred over UFH due to lower bleeding risk 1, 3
• If VKA is used, overlap with parenteral anticoagulation until INR reaches 2.0-3.0 (target 2.5) 1

Duration of Treatment:

• Minimum 3 months of therapeutic anticoagulation for all patients 1, 3
• Discontinue after 3 months if PE was provoked by a major transient/reversible risk factor (e.g., surgery, trauma) 1
• Consider indefinite anticoagulation for unprovoked PE or persistent risk factors, given the favorable safety profile of DOACs and high recurrence risk after cessation 3, 4

Special Considerations:

• Selected low-risk patients can be considered for early discharge and outpatient treatment 1
• DOACs are contraindicated in severe renal impairment (CrCl <30 mL/min), pregnancy, and antiphospholipid syndrome 1

---

Submassive PE (Intermediate-Risk, Hemodynamically Stable with RV Dysfunction)

Do NOT routinely use thrombolysis for intermediate-risk PE; treat with therapeutic anticoagulation alone and close monitoring for deterioration. 5, 6

Initial Management:

• Start anticoagulation immediately with LMWH, fondaparinux, or a DOAC 1
• In patients with severe renal impairment (CrCl <30 mL/min), use unfractionated heparin with weight-adjusted bolus and target aPTT 1.5-2.5 times normal 5
• Avoid DOACs and LMWH in severe renal impairment due to contraindications and bleeding risk 5

Monitoring Strategy:

• Close monitoring is essential to identify hemodynamic deterioration requiring rescue therapy 5
• Monitor for persistent hypotension, new vasopressor requirement, worsening hypoxemia, altered mental status, or rising lactate 5
• Serial echocardiography and cardiac biomarkers help identify clinical deterioration 5

Hemodynamic Support:

• Avoid aggressive fluid boluses, as they worsen RV failure by increasing RV afterload 5
• Use vasopressors (norepinephrine and/or dobutamine) if hypotension develops 5
• Administer supplemental oxygen for hypoxemia 5

Rescue Thrombolysis:

• Reserve thrombolysis only for rescue therapy if the patient develops hemodynamic deterioration despite adequate anticoagulation 5, 6
• The European Society of Cardiology gives a Class III recommendation against routine thrombolysis in intermediate-risk PE due to increased bleeding risk 6

Advanced Interventions:

• Consider activating a Pulmonary Embolism Response Team (PERT) for complex cases with multiple comorbidities 5, 6
• Mechanical thrombectomy (e.g., Inari FlowTriever) can be considered for intermediate-risk patients who deteriorate despite anticoagulation 6

---

Massive PE (High-Risk, Hemodynamically Unstable)

Administer systemic thrombolytic therapy immediately for high-risk PE with cardiogenic shock or persistent hypotension (systolic BP <90 mmHg for ≥15 minutes). 6, 1

Immediate Actions:

• Initiate unfractionated heparin with weight-adjusted bolus without delay while preparing thrombolysis 6, 1
• Systemic thrombolysis is the first-line treatment with Class I, Level B recommendation 6, 1
• Administer vasopressors (norepinephrine and/or dobutamine) for hemodynamic support 1

Thrombolytic Therapy:

• Thrombolysis is indicated for sustained hypotension, shock, or pulselessness 6
• Check for absolute contraindications: hemorrhagic stroke history, ischemic stroke within 6 months, CNS neoplasm, major trauma/surgery/head injury within 3 weeks, or active bleeding 6
• Relative contraindications include TIA within 6 months, oral anticoagulation, pregnancy, non-compressible puncture sites, and refractory hypertension 6

Alternative Interventions When Thrombolysis Fails or Is Contraindicated:

• Surgical pulmonary embolectomy is recommended (Class I, Level C) if thrombolysis is contraindicated or fails 6, 1
• Percutaneous catheter-directed treatment should be considered (Class IIa, Level C) as an alternative 6, 1
• Mechanical thrombectomy with FlowTriever (24F aspiration device) is FDA-cleared for acute PE and recommended for hemodynamically unstable patients with thrombolysis contraindications 6

Post-Intervention Management:

• Transition to therapeutic anticoagulation once stabilized 1
• Continue anticoagulation for at least 3 months, with consideration for indefinite therapy depending on risk factors 1

---

Special Populations

Cancer Patients:

• LMWH is superior to warfarin for cancer-associated thrombosis 5
• Administer at least 6 months of LMWH, followed by continued LMWH or VKA as long as cancer is active 5
• Apixaban, edoxaban, and rivaroxaban are effective alternatives to LMWH in cancer patients 3

Severe Renal Impairment:

• Use unfractionated heparin exclusively in severe renal impairment (CrCl <30 mL/min) 5
• DOACs and LMWH are contraindicated 5
• If CrCl is 30-50 mL/min, dose-adjusted LMWH may be considered with careful monitoring 5

Pregnancy:

• Use therapeutic fixed doses of LMWH based on early pregnancy weight 1
• DOACs and VKAs are contraindicated in pregnancy 1

Antiphospholipid Syndrome:

• Continue VKA indefinitely; DOACs are contraindicated 1

---

IVC Filters

IVC filters should be considered only in acute PE with absolute contraindications to anticoagulation (Class IIa, Level C) 1

• Routine use of IVC filters is NOT recommended (Class III, Level A) 1

---

Follow-Up

All patients should be routinely re-evaluated 3-6 months after acute PE to assess for chronic thromboembolic pulmonary hypertension and persistent symptoms 1